Michael E. Borden, Author at GoodLifeSci

About Michael E. Borden

Washington, D.C.

Entries by Michael E. Borden

13 09 '24

As U.S. Biosecure Act Passes the House, Four Things Biotechs Can Do to Prepare

September 13, 2024/in Antitrust/Competition, APAC, Drug Discovery, Drug Pricing, FDA, FDA Guidance, Global Drug Pricing, Global Life Sciences, Investigations, Pharmaceutical, Regulatory, Supply Chain/by Michael E. Borden

The U.S. Senate may still reject the U.S. BIOSECURE Act , but the House of Representatives has now passed a version of the bill. Biotechs in both the P.R.C. and the U.S. therefore need to prepare for the new environment which it heralds. Michael Borden, Andrew Shoyer, and Ruchun Ji set out five steps to take now.

19 08 '24

How, When, and If the U.S. BIOSECURE Act Is Likely to Become Law

August 19, 2024/in Antitrust/Competition, APAC, Drug Discovery, Drug Pricing, FDA, FDA Guidance, Global Drug Pricing, Global Life Sciences, Investigations, Pharmaceutical, Regulatory, Supply Chain/by Michael E. Borden

Both U.S. and P.R.C.-based biotechs are anxiously watching attempts to pass the U.S. BIOSECURE Act into law. Michael Borden and Andrew Shoyer explain what this month’s developments mean, and why the legislation, even with so much attention and publicity, may never actually become law.

About Michael E. Borden

Entries by Michael E. Borden

SUBSCRIBE